Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China

References

• Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399–1408.
   PubMed Web of Science ®Google Scholar
• World Health Organization [Internet]. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. 2021 Jul. Available from: https://www.who.int/publications/i/item/9789240027077.
   Google Scholar
• Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.
   PubMed Web of Science ®Google Scholar
• Xia GL, Liu CB, Cao HL, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int Hepatol Commun. 1996;5(1):62–73.
   Web of Science ®Google Scholar
• Transforming our world: the 2030 agenda for sustainable development. United Nations General Assembly, Seventieth Session. New York, the United States of America; 2015 Sep 25s cited 2021 Apr 21. Available from: https://www.un.org/ga/search/view_doc.asp?symbol=A/RES/70/1&Lang=E
   Google Scholar
• Syed-Ahmed M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(1):8–15.
   PubMed Web of Science ®Google Scholar
• Krueger KM, Ison MG, Ghossein C, et al. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis. 2020;75(3):417–425.
   PubMed Web of Science ®Google Scholar
• Descamps-Latscha B. The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens. 1993;2(6):883–891.
   PubMedGoogle Scholar
• Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5):1526–1533.
   PubMed Web of Science ®Google Scholar
• GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–733.
   PubMed Web of Science ®Google Scholar
• Mulley WR, Le ST, Ives KE, et al. Primary seroresponses to double-dose compared with standard-dose hepatitis B vaccination in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32(1):136–143.
   PubMed Web of Science ®Google Scholar
• Ahmadi F, Ramezani M, Razeghi E, et al. A randomized controlled trial of two schedules of hepatitis B vaccination in predialysed chronic renal failure patients. Hepat Mon. 2012;12(5):344–348.
   PubMed Web of Science ®Google Scholar
• Ghadiani MH, Besharati S, Mousavinasab N, et al. Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients. J Res Med Sci. 2012;17(6):527–533.
   PubMed Web of Science ®Google Scholar
• Da Silva EN, Baker A, Alshekaili J, et al. A randomized trial of serological and cellular responses to hepatitis B vaccination in chronic kidney disease. PLoS One. 2018;13(10):e0204477.
   PubMed Web of Science ®Google Scholar
• McNulty CA, Bowen JK, Williams AJ, et al. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules. Vaccine. 2005;23(32):4142–4147.
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Malik A, Shukla I, et al. Seroprotection after hepatitis B vaccination in chronic kidney disease patients with modified schedule and dosage. J Infect Dev Ctries. 2010;4(6):389–392.
   PubMed Web of Science ®Google Scholar
• Chow KM, Law MC, Leung CB, et al. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract. 2006;103(3):c89–93.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Martin P, Messa P. Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population. Int J Artif Organs. 2015;38(12):625–631.
   PubMed Web of Science ®Google Scholar
• Lin SY, Liu JH, Lin CC, et al. Comparison of hepatitis B surface antibody decay rates after vaccination between hemodialysis and peritoneal dialysis patients. Vaccine. 2011;29(21):3738–3741.
   PubMed Web of Science ®Google Scholar
• Bruce MG, Bruden D, Hurlburt D, et al. Antibody levels and protection after hepatitis B Vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214(1):16–22.
   PubMed Web of Science ®Google Scholar
• Chinese Society of Infectious Diseases, Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Zhonghua Gan Zang Bing Za Zhi. 2019;27(12):938–961.
   PubMedGoogle Scholar
• DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42(6):1184–1192.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Bunnapradist S, et al. Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. Aliment Pharmacol Ther. 2006;23(8):1105–1112.
   PubMed Web of Science ®Google Scholar
• Krairittichai U, Sethakarun S. A randomized controlled trial of seroconversion after 20 mg versus 40 mg intramuscular hepatitis B virus vaccination in patients with chronic kidney disease stage 3. J Med Assoc Thai. 2017;100(Suppl 1):S1–7.
   PubMedGoogle Scholar
• Feng YL, Yao T, Han YJ, et al. Immunogenicity and safety of a high-dose and prolonged-schedule hepatitis B vaccine among chronic kidney disease patients: a randomized, parallel-controlled trial. Expert Rev Vaccines. 2021;20(6):743–751.
   PubMed Web of Science ®Google Scholar
• Gilbert CL, Stek JE, Villa G, et al. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients. Vaccine. 2014;32(48):6521–6526.
   PubMed Web of Science ®Google Scholar
• Dimitrov Y, Ducher M, Kribs M, et al. Variables linked to hepatitis B vaccination success in non-dialyzed chronic kidney disease patients: use of a Bayesian model. Nephrol Ther. 2019;15(4):215–219.
   PubMed Web of Science ®Google Scholar
• Lacson E, Teng M, Ong J, et al. Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease. Hemodial Int. 2005;9(4):367–375.
   PubMedGoogle Scholar
• Lopes VB, Hassing RJ, de Vries-Sluijs TE, et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine. 2013;31(7):1040–1044.
   PubMed Web of Science ®Google Scholar
• Chaves SS, Daniels D, Cooper BW, et al. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. Vaccine. 2011;29(52):9618–9623.
   PubMed Web of Science ®Google Scholar
• European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on hepatitis B immunity. Lancet. 2000;355(9203):561–565.
   PubMed Web of Science ®Google Scholar
• Laplanche A, Courouce AM, Benhamou E, et al. Timing of hepatitis B revaccination in healthy adults. Lancet. 1987;1(8543):1206–1207.
   PubMed Web of Science ®Google Scholar
• FitzSimons D, Hendrickx G, Vorsters A, et al. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. Vaccine. 2013;31(4):584–590.
   PubMed Web of Science ®Google Scholar
• Sester U, Schmidt T, Kuhlmann MK, et al. Serial influenza-vaccination reveals impaired maintenance of specific T-cell memory in patients with end-stage renal failure. Vaccine. 2013;31(38):4111–4120.
   PubMed Web of Science ®Google Scholar
• Launay O, Rosenberg AR, Rey D, et al. Long-term immune response to hepatitis B virus vaccination regimens in adults with human immunodeficiency virus 1: secondary analysis of a randomized clinical trial. JAMA Intern Med. 2016;176(5):603–610.
   PubMed Web of Science ®Google Scholar
• el-Reshaid K, al-Mufti S, Johny KV, et al. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. Vaccine. 1994;12(3):223–234.
   PubMed Web of Science ®Google Scholar
• Janssen RS, Mangoo-Karim R, Pergola PE, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine. 2013;31(46):5306–5313.
   PubMed Web of Science ®Google Scholar
• Windpessl M, Heine GH, Becker SL, et al. The impact of immunosuppression and chronic kidney disease on immunogenicity of COVID-19 vaccines. Dtsch Med Wochenschr. 2021;146(19):1277–1282.
   PubMed Web of Science ®Google Scholar
• Eickenberg S, Mickholz E, Jung E, et al. Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R110.
   PubMed Web of Science ®Google Scholar
• Papp KA, Haraoui B, Kumar D, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019;23(1):50–74.
   PubMed Web of Science ®Google Scholar
• Feng YL, Han YJ, Yao T, et al. Immunogenicity and influencing factors of hepatitis B vaccination based on different vaccination schedules among chronic kidney disease patients. Chin J Epidemiol. 2022;43(2):241–247.
   Google Scholar